Arno Therapeutics (ARNI) 0.3509 $ARNI
Arno Therapeutics Reports First Quarter 2016 Financial and Business Update
GlobeNewswire - Mon May 16, 3:30PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced financial results for the quarter ended March 31, 2016 and provided an update on recent clinical developments for its lead compound, onapristone.
UCLA's Dr. Stuart Holden Interviewed by The Life Sciences Report
Marketwired - Thu Apr 21, 8:02AM CDT
Solid tumors are typically managed with surgical resection, chemotherapy, radiation and biologics, but it's the secondary tumor mass, the metastasis, that kills patients. Dr. Stuart Holden of the UCLA Institute of Urologic Oncology understands the importance of targeting metastatic disease, which is driven by different genetic factors than the primary tumor from which it arose -- a fact that oncologists are just now coming to grips with. In this interview with The Life Sciences Report, Dr. Holden describes an essential target in aggressive prostate cancers, and a drug with the potential to address that target and extend the lives of thousands of men.
Arno Therapeutics to Focus Clinical Developmental Activities on Advanced Prostate Cancer in First-of-its-Kind Phase II Study of Onapristone in Combination with ZYTIGA(R)
GlobeNewswire - Tue Apr 19, 7:00AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company dedicated to the development of therapeutics for cancer and other life threatening diseases, today announced that it has determined to focus its onapristone development program on metastatic castration-resistant prostate cancer (CRPC) that has become resistant to ZYTIGA(R) (abiraterone acetate) therapy. To support this milestone decision, Arno Therapeutics is pleased to announce the formation of a special Prostate Cancer Advisory Board.
Arno Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update
GlobeNewswire - Wed Mar 30, 3:17PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced financial results for the fourth quarter and full year of 2015 and provided an update on recent clinical developments for its lead compound, onapristone.
Arno Therapeutics Advances Phase I/II Trial Evaluating Onapristone in Prostate Cancer to Phase II
GlobeNewswire - Mon Mar 21, 6:30AM CDT
- Phase II to include study of onapristone in combination with abiraterone -
Direction of Market Influences - Featured Research on Cannabis Science, Hancock Fabrics, Arno Therapeutics and Striker Exploration
ACCESSWIRE - Tue Jan 19, 8:10AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Cannabis Science Inc. (OTC: CBIS), Hancock Fabrics Inc. (OTC: HKFI), Arno Therapeutics Inc. (OTC: ARNI) and Striker Exploration Corp (OTC: EKWFF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Arno Therapeutics Completes $7.4 Million Common Stock Financing
GlobeNewswire - Wed Jan 13, 6:30AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that it has completed a private placement of its common stock resulting in gross proceeds to the company of approximately $7.4 million, which includes approximately $2.1 million through the automatic conversion of convertible promissory notes issued by the company in October 2015. The financing was led by the Company's existing investors, including affiliates of Chairman, Arie Belldegrun, MD, OPKO Health, Inc., Soros Fund Management, LLC, Commercial Street Capital LLC, Pontifax, Bonderman Family Limited Partnership, Perceptive Advisors LLC and Auriga Capital Management. The Company intends to use the proceeds from this financing to fund its ongoing clinical development of onapristone, its lead product candidate, and for general corporate purposes.
OPK: 9.78 (-0.11)
Arno Therapeutics Reports Third Quarter 2015 Financial Results and Business Update
GlobeNewswire - Mon Nov 16, 3:00PM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced financial results for the quarter ended September 30, 2015 and provided an update on recent clinical developments for its lead oncology compound, onapristone.
Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis
GlobeNewswire - Thu Oct 29, 6:01AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced data demonstrating that AR-12 is a promising novel antifungal agent for the treatment of onychomycosis, a common fungal infection of the fingernails and toenails, with activity against two primary fungal organisms responsible for causing the condition. Results will be presented in a poster presentation, titled "Trans-ungual Delivery of AR-12, a Novel Antifungal Drug" (Poster R6046), on Thursday, October 29 during the 2015 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, being held in Orlando, FL.
Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains
GlobeNewswire - Wed Oct 21, 9:01AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced data demonstrating that AR-12 has potent in vitro antiviral activity against HIV-1, HIV-2 and drug-resistant HIV-1. Results were presented today in a poster presentation during the 15 European AIDS Conference, which is hosted by the European AIDS Clinical Society (EACS) and being held October 21-24 in Barcelona, Spain.
Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference
GlobeNewswire - Fri Sep 25, 5:00AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that a late-breaking abstract on AR-12 has been accepted for poster presentation at the upcoming 15 European AIDS Conference, hosted by the European AIDS Clinical Society (EACS) and being held October 21-24 in Barcelona, Spain.
Arno Therapeutics' AR-13 Data Show Promise as Potential New Therapeutic Option for Cystic Fibrosis Patients With Serious Bacterial Infections
GlobeNewswire - Thu Sep 24, 6:00AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced data from a preclinical study demonstrating AR-13, an analogue of the Company's AR-12 infectious disease compound portfolio, has promise as a potential new therapeutic option for patients with cystic fibrosis (CF) acutely and chronically infected with Burkholderia cenocepacia and other antibiotic resistant organisms such as Pseudomonas aeruginosa.
Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs
GlobeNewswire - Sat Sep 19, 3:00PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced promising data demonstrating novel activity of AR-12 as a broad-spectrum, anti-microbial drug. Results were presented over the weekend in a podium presentation and in posters at ICAAC/ICC 2015 (Interscience Conference of Antimicrobial Agents and Chemotherapy / International Congress of Chemotherapy and Infection), which is jointly hosted by the American Society for Microbiology (ASM) and International Society of Chemotherapy (ISC) and took place September 17-21 in San Diego, CA.
Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Exposition
GlobeNewswire - Sat Sep 19, 7:00AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that an abstract outlining data supporting AR-12 as a novel anti-fungal drug has been accepted for presentation at the upcoming 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, being held October 25-29 in Orlando, FL.
AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015
GlobeNewswire - Mon Sep 14, 7:00AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that four abstracts supporting the ongoing development of AR-12 as a broad-spectrum, antimicrobial drug have been accepted for presentation, one of which will be a podium presentation, at the upcoming Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) / International Congress of Chemotherapy and Infection (ICC) 2015, jointly hosted by the American Society for Microbiology (ASM) and International Society of Chemotherapy (ISC), and being held September 17-21, 2015 in San Diego, CA.
Arno Therapeutics to Present at 17th Annual Rodman & Renshaw Conference
GlobeNewswire - Tue Sep 01, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that Alexander Zukiwski, Chief Executive Officer & Chief Medical Officer of Arno Therapeutics is scheduled to present at the 17 Annual Rodman & Renshaw Global Investment conference being held September 8-10, 2015 in New York, NY.
Arno Therapeutics passes approval to enroll patients in second stage of Phase I/II clinical trial of onapristone in prostate cancer in the UK
M2 - Wed Aug 19, 5:48AM CDT
Biopharmaceutical company Arno Therapeutics (OtherOTC:ARNI) reported on Tuesday that it has received approval from the Medicines and Healthcare products Regulatory Authority (MHRA) to begin enrolling patients in the second stage of its Phase I/II clinical trial evaluating lead compound onapristone in men with advanced castration-resistant prostate cancer (CRPC) in the UK.
Arno Therapeutics Receives Authorization to Proceed With Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer
GlobeNewswire - Tue Aug 18, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced that it has received authorization from the Medicines and Healthcare products Regulatory Authority (MHRA) to begin enrolling patients in the United Kingdom in the second stage of its Phase I/II clinical trial evaluating lead compound onapristone in men with advanced castration-resistant prostate cancer (CRPC). An independent data review committee has determined the recommended Phase II dose of single agent onapristone to be 50mg extended release tablets, taken twice daily. The second stage protocol has been modified to evaluate onapristone in combination with abiraterone (Zytiga(R)) in patients with CRPC that expresses the progesterone receptor (PR) or the T878A androgen receptor (AR) mutation. The AR T878 receptor mutation has been demonstrated to bind progesterone. The second stage of the study also includes a Phase II cohort of patients with PR-positive CRPC who will receive single agent onapristone.
Arno Therapeutics Reports Second Quarter 2015 Financial Results and Business Update
GlobeNewswire - Fri Aug 14, 4:08PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced financial results for the quarter ended June 30, 2015 and provided an update on recent clinical developments for its lead oncology compound, onapristone.
Arno Therapeutics Announces Issuance of First Onapristone Patent
GlobeNewswire - Thu Jun 04, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that United States Patent Number 9,046,534 has been issued by the U.S. Patent and Trademark Office (USPTO) related to the methods and systems for identifying and treating patients with anti-progestin sensitive tumors using the Company's lead product candidate, onapristone. The patent, which Arno has exclusively licensed from Invivis Pharmaceuticals, Inc., establishes that the focal nuclear distribution pattern of the progesterone receptor can be used to identify tumors susceptible to treatment with anti-progestin therapy.
Arno Therapeutics Reports First Quarter 2016 Financial and Business Update
GlobeNewswire - Mon May 16, 3:30PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced financial results for the quarter ended March 31, 2016 and provided an update on recent clinical developments for its lead compound, onapristone.
UCLA's Dr. Stuart Holden Interviewed by The Life Sciences Report
Marketwired - Thu Apr 21, 8:02AM CDT
Solid tumors are typically managed with surgical resection, chemotherapy, radiation and biologics, but it's the secondary tumor mass, the metastasis, that kills patients. Dr. Stuart Holden of the UCLA Institute of Urologic Oncology understands the importance of targeting metastatic disease, which is driven by different genetic factors than the primary tumor from which it arose -- a fact that oncologists are just now coming to grips with. In this interview with The Life Sciences Report, Dr. Holden describes an essential target in aggressive prostate cancers, and a drug with the potential to address that target and extend the lives of thousands of men.
Arno Therapeutics to Focus Clinical Developmental Activities on Advanced Prostate Cancer in First-of-its-Kind Phase II Study of Onapristone in Combination with ZYTIGA(R)
GlobeNewswire - Tue Apr 19, 7:00AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company dedicated to the development of therapeutics for cancer and other life threatening diseases, today announced that it has determined to focus its onapristone development program on metastatic castration-resistant prostate cancer (CRPC) that has become resistant to ZYTIGA(R) (abiraterone acetate) therapy. To support this milestone decision, Arno Therapeutics is pleased to announce the formation of a special Prostate Cancer Advisory Board.
Arno Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update
GlobeNewswire - Wed Mar 30, 3:17PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced financial results for the fourth quarter and full year of 2015 and provided an update on recent clinical developments for its lead compound, onapristone.
Arno Therapeutics Advances Phase I/II Trial Evaluating Onapristone in Prostate Cancer to Phase II
GlobeNewswire - Mon Mar 21, 6:30AM CDT
- Phase II to include study of onapristone in combination with abiraterone -
Direction of Market Influences - Featured Research on Cannabis Science, Hancock Fabrics, Arno Therapeutics and Striker Exploration
ACCESSWIRE - Tue Jan 19, 8:10AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Cannabis Science Inc. (OTC: CBIS), Hancock Fabrics Inc. (OTC: HKFI), Arno Therapeutics Inc. (OTC: ARNI) and Striker Exploration Corp (OTC: EKWFF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Arno Therapeutics Completes $7.4 Million Common Stock Financing
GlobeNewswire - Wed Jan 13, 6:30AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that it has completed a private placement of its common stock resulting in gross proceeds to the company of approximately $7.4 million, which includes approximately $2.1 million through the automatic conversion of convertible promissory notes issued by the company in October 2015. The financing was led by the Company's existing investors, including affiliates of Chairman, Arie Belldegrun, MD, OPKO Health, Inc., Soros Fund Management, LLC, Commercial Street Capital LLC, Pontifax, Bonderman Family Limited Partnership, Perceptive Advisors LLC and Auriga Capital Management. The Company intends to use the proceeds from this financing to fund its ongoing clinical development of onapristone, its lead product candidate, and for general corporate purposes.
OPK: 9.78 (-0.11)
Arno Therapeutics Reports Third Quarter 2015 Financial Results and Business Update
GlobeNewswire - Mon Nov 16, 3:00PM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced financial results for the quarter ended September 30, 2015 and provided an update on recent clinical developments for its lead oncology compound, onapristone.
Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis
GlobeNewswire - Thu Oct 29, 6:01AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced data demonstrating that AR-12 is a promising novel antifungal agent for the treatment of onychomycosis, a common fungal infection of the fingernails and toenails, with activity against two primary fungal organisms responsible for causing the condition. Results will be presented in a poster presentation, titled "Trans-ungual Delivery of AR-12, a Novel Antifungal Drug" (Poster R6046), on Thursday, October 29 during the 2015 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, being held in Orlando, FL.
Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains
GlobeNewswire - Wed Oct 21, 9:01AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced data demonstrating that AR-12 has potent in vitro antiviral activity against HIV-1, HIV-2 and drug-resistant HIV-1. Results were presented today in a poster presentation during the 15 European AIDS Conference, which is hosted by the European AIDS Clinical Society (EACS) and being held October 21-24 in Barcelona, Spain.
Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference
GlobeNewswire - Fri Sep 25, 5:00AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that a late-breaking abstract on AR-12 has been accepted for poster presentation at the upcoming 15 European AIDS Conference, hosted by the European AIDS Clinical Society (EACS) and being held October 21-24 in Barcelona, Spain.
Arno Therapeutics' AR-13 Data Show Promise as Potential New Therapeutic Option for Cystic Fibrosis Patients With Serious Bacterial Infections
GlobeNewswire - Thu Sep 24, 6:00AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced data from a preclinical study demonstrating AR-13, an analogue of the Company's AR-12 infectious disease compound portfolio, has promise as a potential new therapeutic option for patients with cystic fibrosis (CF) acutely and chronically infected with Burkholderia cenocepacia and other antibiotic resistant organisms such as Pseudomonas aeruginosa.
Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs
GlobeNewswire - Sat Sep 19, 3:00PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced promising data demonstrating novel activity of AR-12 as a broad-spectrum, anti-microbial drug. Results were presented over the weekend in a podium presentation and in posters at ICAAC/ICC 2015 (Interscience Conference of Antimicrobial Agents and Chemotherapy / International Congress of Chemotherapy and Infection), which is jointly hosted by the American Society for Microbiology (ASM) and International Society of Chemotherapy (ISC) and took place September 17-21 in San Diego, CA.
Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Exposition
GlobeNewswire - Sat Sep 19, 7:00AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that an abstract outlining data supporting AR-12 as a novel anti-fungal drug has been accepted for presentation at the upcoming 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, being held October 25-29 in Orlando, FL.
AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015
GlobeNewswire - Mon Sep 14, 7:00AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that four abstracts supporting the ongoing development of AR-12 as a broad-spectrum, antimicrobial drug have been accepted for presentation, one of which will be a podium presentation, at the upcoming Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) / International Congress of Chemotherapy and Infection (ICC) 2015, jointly hosted by the American Society for Microbiology (ASM) and International Society of Chemotherapy (ISC), and being held September 17-21, 2015 in San Diego, CA.
Arno Therapeutics to Present at 17th Annual Rodman & Renshaw Conference
GlobeNewswire - Tue Sep 01, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that Alexander Zukiwski, Chief Executive Officer & Chief Medical Officer of Arno Therapeutics is scheduled to present at the 17 Annual Rodman & Renshaw Global Investment conference being held September 8-10, 2015 in New York, NY.
Arno Therapeutics passes approval to enroll patients in second stage of Phase I/II clinical trial of onapristone in prostate cancer in the UK
M2 - Wed Aug 19, 5:48AM CDT
Biopharmaceutical company Arno Therapeutics (OtherOTC:ARNI) reported on Tuesday that it has received approval from the Medicines and Healthcare products Regulatory Authority (MHRA) to begin enrolling patients in the second stage of its Phase I/II clinical trial evaluating lead compound onapristone in men with advanced castration-resistant prostate cancer (CRPC) in the UK.
Arno Therapeutics Receives Authorization to Proceed With Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer
GlobeNewswire - Tue Aug 18, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced that it has received authorization from the Medicines and Healthcare products Regulatory Authority (MHRA) to begin enrolling patients in the United Kingdom in the second stage of its Phase I/II clinical trial evaluating lead compound onapristone in men with advanced castration-resistant prostate cancer (CRPC). An independent data review committee has determined the recommended Phase II dose of single agent onapristone to be 50mg extended release tablets, taken twice daily. The second stage protocol has been modified to evaluate onapristone in combination with abiraterone (Zytiga(R)) in patients with CRPC that expresses the progesterone receptor (PR) or the T878A androgen receptor (AR) mutation. The AR T878 receptor mutation has been demonstrated to bind progesterone. The second stage of the study also includes a Phase II cohort of patients with PR-positive CRPC who will receive single agent onapristone.
Arno Therapeutics Reports Second Quarter 2015 Financial Results and Business Update
GlobeNewswire - Fri Aug 14, 4:08PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced financial results for the quarter ended June 30, 2015 and provided an update on recent clinical developments for its lead oncology compound, onapristone.
Arno Therapeutics Announces Issuance of First Onapristone Patent
GlobeNewswire - Thu Jun 04, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that United States Patent Number 9,046,534 has been issued by the U.S. Patent and Trademark Office (USPTO) related to the methods and systems for identifying and treating patients with anti-progestin sensitive tumors using the Company's lead product candidate, onapristone. The patent, which Arno has exclusively licensed from Invivis Pharmaceuticals, Inc., establishes that the focal nuclear distribution pattern of the progesterone receptor can be used to identify tumors susceptible to treatment with anti-progestin therapy.
